As discussed in the first article in this continuing medical education series, angioinvasive fungal infections pose a significant risk to immunocompromised and immunocompetent patients alike, with a potential for severe morbidity and high mortality. The first article in this series focused on the epidemiology and clinical presentation of these infections; this article discusses the diagnosis, management, and potential complications of these infections. The mainstay diagnostic tests (positive tissue culture with histologic confirmation) are often supplemented with serum biomarker assays and molecular testing (eg, quantitative polymerase chain reaction analysis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry) to ensure proper speciation. When an angioinvasive fungal infection is suspected or diagnosed, further workup for visceral involvement also is essential and may partially depend on the organism. Different fungal organisms have varied susceptibilities to antifungal agents, and knowledge on optimal treatment regimens is important to avoid the potential complications associated with undertreated or untreated fungal infections.Le texte complet de cet article est disponible en PDF.
Key words : angioinvasive fungal infections, antifungal therapy, aspergillosis, candidiasis, fusariosis, mucormycetes
| Date of release: April 2019
| Expiration date: April 2022
| Dr Wanat is currently affiliated with the Medical College of Wisconsin, Department of Dermatology, Milwaukee, WI.
| Dr Wanat received a Dermatology Foundation Career Development Award.
| Conflicts of interest: None disclosed.